Viral Origin of KS Appears Confirmed

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 3
Volume 4
Issue 3

WASHINGTON--New research presented at the 2nd National Conference on Human Retroviruses and Related Infections appears to confirm last year's report that a virus is the cause of Kaposi's sarcoma (KS). Its discoverers, Drs. Patrick S. Moore and Yuan Chang of Columbia University, are calling the virus Kaposi sarcoma-associated herpesvirus (KSHV).

WASHINGTON--New research presented at the 2nd National Conferenceon Human Retroviruses and Related Infections appears to confirmlast year's report that a virus is the cause of Kaposi's sarcoma(KS). Its discoverers, Drs. Patrick S. Moore and Yuan Chang ofColumbia University, are calling the virus Kaposi sarcoma-associatedherpesvirus (KSHV).

The researchers announced that they have mapped the virus's basicgenetic structure and found that it is the largest known herpesvirus,containing DNA made up of 270,000 nucleotide base pairs.

They have consistently found the genetic sequence for KSHV intissue samples from people with KS who are HIV negative. The viruswas noted in six samples from people with classic KS (usuallyfound in elderly Mediterranean men), four from HIV-negative gaymen, and 10 from Africans with endemic African KS.

Related Videos
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.